Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695435 · ClinicalTrials.gov registry record · Phase 1
Tobramycin Tear Concentrations
A Phase 1 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00695435 is a Phase 1 study that has completed, run by Alcon Research. The registered enrollment target is 21 participants.
The verdict
NCT00695435, a Phase 1 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.
Interventions
- DRUG TOBRADEX Ophthalmic Suspension
- DRUG Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
- DRUG TOBREX Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00695435
The ClinicalTrials.gov registry entry for NCT00695435 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TOBRADEX Ophthalmic Suspension is the first listed.
NCT00695435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00695435 about?
NCT00695435 is a clinical study titled "Tobramycin Tear Concentrations". To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.
What is the current status of trial NCT00695435?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2008-06.
What interventions are being tested in trial NCT00695435?
The interventions under investigation include: TOBRADEX Ophthalmic Suspension (DRUG), Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension (DRUG), TOBREX Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT00695435?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.